Gritstone - Bispecific Antibody Therapeutic (BiSAb)
From Our Pipeline
Gritstone has a program focused on the development of bispecific antibody (BiSAb) therapeutics using highly tumor-specific antigens, including neoantigens, shared between patients with various solid tumors. Our lead BiSAb candidate is currently in IND-enabling studies. The target of this lead program is CT83, a cancer-germline antigen which is highly expressed on certain solid tumors and has limited/low expression on normal tissues.
Customer reviews
No reviews were found for Gritstone - Bispecific Antibody Therapeutic (BiSAb). Be the first to review!